CD274 and non-small cell lung carcinoma: Thus, two scoring systems have been adopted in clinical trials: the percentage of stained tumor cells, which is substantially the same as the tumor proportion score (TPS) used in NSCLC, and CPS, which assesses all PD‐L1+ cells including tumor cells, lymphocytes, and macrophages (Table 3).